Last reviewed · How we verify
Generic HAART Triomune : d4T, 3TC, NVP
Triomune is a fixed-dose combination antiretroviral therapy that inhibits HIV reverse transcriptase and protease to suppress viral replication.
Triomune is a fixed-dose combination antiretroviral therapy that inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Generic HAART Triomune : d4T, 3TC, NVP |
|---|---|
| Sponsor | University of KwaZulu |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
The combination contains stavudine (d4T), a nucleoside reverse transcriptase inhibitor; lamivudine (3TC), a nucleoside reverse transcriptase inhibitor; and nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor. Together, these agents block HIV reverse transcriptase through different mechanisms, preventing the virus from converting its RNA genome into DNA and integrating into host cells, thereby suppressing viral replication and allowing immune reconstitution.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Peripheral neuropathy
- Hepatotoxicity
- Rash
- Lipodystrophy
- Lactic acidosis
- Pancreatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic HAART Triomune : d4T, 3TC, NVP CI brief — competitive landscape report
- Generic HAART Triomune : d4T, 3TC, NVP updates RSS · CI watch RSS
- University of KwaZulu portfolio CI